We are live on ! Find out more
GNCA

Genocea Biosciences, Inc.
GNCA

Delisted

GNCA was delisted on the 2nd of June, 2022.

Back to rankings

49 hedge funds and large institutions have $94M invested in Genocea Biosciences, Inc. in 2017 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 15 increasing their positions, 5 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,055% more call options, than puts

Call options by funds: $127K | Put options by funds: $11K

200% more repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 5

86% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 7

47% more capital invested

Capital invested by funds: $64M → $94M (+$30M)

4% more funds holding

Funds holding: 47 → 49 (+2)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

Holders
49
Holders Change
+2
Holders Change %
+4.26%
% of All Funds
1.22%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
13
Increased
15
Reduced
5
Closed
7
Calls
$127K
Puts
$11K
Net Calls
+$116K
Net Calls Change
+$85K

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$1.41M
2
WA
Wasatch Advisors
Utah
+$484K
3
Vanguard Group
Vanguard Group
Pennsylvania
+$376K
4
JP Morgan Chase
JP Morgan Chase
New York
+$174K
5
BCM
Bridgeway Capital Management
Texas
+$156K

Top Sellers

Rank Fund Capital Flow
1
DM
Deerfield Management
New York
-$1.02M
2
NC
Northpointe Capital
Michigan
-$865K
3
SFM
Sphera Funds Management
Israel
-$244K
4
VKH
Virtu KCG Holdings
New York
-$225K
5
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$107K
Name Holding Trade Value Shares
Change 		Change in
Stake
T. Rowe Price Associates
26
T. Rowe Price Associates
Maryland
$145K +$117K +2,982 New
State Street
27
State Street
Massachusetts
$131K – – –
Ameriprise
28
Ameriprise
Minnesota
$121K +$24.8K +634 +34%
Barclays
29
Barclays
United Kingdom
$104K +$83K +2,125 New
Morgan Stanley
30
Morgan Stanley
New York
$99K +$37.3K +954 +88%
GP
31
GLG Partners
United Kingdom
$94K +$75K +1,920 New
HLA
32
Hamilton Lane Advisors
Pennsylvania
$82K +$65.6K +1,679 New
AAM
33
Aberdeen Asset Management
United Kingdom
$76K +$61.4K +1,570 New
Bank of New York Mellon
34
Bank of New York Mellon
New York
$74K – – –
MCM
35
Manchester Capital Management
Vermont
$72K +$57.6K +1,473 New
TSS
36
Two Sigma Securities
New York
$63K +$50.9K +1,302 New
AWA
37
Artemis Wealth Advisors
New York
$55.4K – – –
Deutsche Bank
38
Deutsche Bank
Germany
$46K +$6.53K +167 +21%
UBS Group
39
UBS Group
Switzerland
$33K +$1.25K +32 +5%
Citigroup
40
Citigroup
New York
$24K – – –
FANJ
41
Financial Architects (New Jersey)
New Jersey
$18K – – –
Manulife (Manufacturers Life Insurance)
42
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$15K +$4.88K +125 +68%
Bank of America
43
Bank of America
North Carolina
$13K +$7.89K +202 +342%
SAM
44
Shamrock Asset Management
Texas
$6K – – –
Wells Fargo
45
Wells Fargo
California
$6K – – –
Royal Bank of Canada
46
Royal Bank of Canada
Ontario, Canada
$3K +$39 +1 +2%
TDC
47
Thompson Davis & Co
Virginia
$3K +$2.46K +63 New
LTFS
48
Ladenburg Thalmann Financial Services
Florida
$2K – – –
VKH
49
Virtu KCG Holdings
New York
– -$225K -6,839 Closed
Jacobs Levy Equity Management
50
Jacobs Levy Equity Management
New Jersey
– -$107K -3,260 Closed
1
2
3

GNCA Hedge Fund Activity: Q1 2017 in Review

49 of the 4,018 institutional investors tracked by Wall St. Rank reported a position in Genocea Biosciences, Inc. (GNCA) for Q1 2017, worth a combined $94M — up 47% from $64M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new GNCA positions and 7 closed out — a net gain of 6 holders — while 15 added to existing stakes and 5 trimmed.

The largest buyer was BlackRock, opening a new position worth an estimated $1.41M. The largest seller was Deerfield Management, cutting an estimated $1.02M.

  • 49 institutional investors held Genocea Biosciences, Inc. (GNCA) as of Q1 2017, up from 47 in Q4 2016.
  • Funds reported $94M of Genocea Biosciences, Inc. stock for Q1 2017, up 47% quarter-over-quarter.
  • 13 funds opened new Genocea Biosciences, Inc. positions in Q1 2017 and 7 closed out, a net change of +6 holders.
  • The largest Genocea Biosciences, Inc. buyer in Q1 2017 was BlackRock, an estimated $1.41M added.
  • The largest Genocea Biosciences, Inc. seller in Q1 2017 was Deerfield Management, an estimated $1.02M sold.

Based on aggregated 13F filings for Q1 2017.